Success Beneath the Surface copertina

Success Beneath the Surface

Success Beneath the Surface

Di: Deborah S. Fell
Ascolta gratuitamente

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

This podcast is aimed at helping CEOs dig beneath the surface to find new pathways to increased profitability. Deborah Fell from Chief Outsiders, will seek to challenge and inspire leadership teams and provide immediately actionable solutions to unlock growth.Copyright 2025 All rights reserved. Economia Gestione e leadership Management
  • EP118: The Venture Studio Model That Launched 285 Companies
    Jan 21 2026

    Michael Poisel left a successful venture capital career in the United States to become Executive Director of the Melbourne Entrepreneurial Centre. His mission is transforming Australia's economy through innovation and company creation.

    After launching 285 companies at the University of Pennsylvania, Michael brought his venture studio model to Melbourne. He helps researchers commercialize their work without becoming entrepreneurs themselves. The approach builds companies for them, finds the management teams, and handles the complex business infrastructure that turns research into viable commercial enterprises.

    Michael shares hard truths about global entrepreneurship—countries where business failure can land you in jail, disappearing R&D budgets at major corporations, and why universities must step into the innovation gap. He explains why 40% of Australian companies have fewer than 10 employees, how he's already started his first Melbourne company with 15 more in the pipeline, and why Australia actually has more accessible capital than the United States.

    For mid-market CEOs facing growth challenges, Michael offers battle-tested wisdom on staying innovative, maintaining urgency, and remembering that if you see a problem, 12 people in China probably do too.

    About Deborah's guest, Michael Poisel

    Michael has spent almost 20 years becoming an expert in spinning out companies from universities. Currently, he's the Executive Director of the Melbourne Entrepreneurial Centre, leading efforts to scale its operations into an enterprise that meets the needs of everyone in the university ecosystem (students, staff, researchers, and alumni). Previously, Michael built entrepreneurial programs at the University of Pennsylvania for over 16 years and was responsible for creating Penn’s internal venture studio, PCI Ventures, which includes UPstart, UPadvisors, and Venture WarmUP. As part of these programs, he participated in the founding of over 280 companies that have raised over $950 million in funding.

    Prior to Penn, Michael made investments in enterprise software and business services for NewSpring Capital, Apax Partners, and GE Capital, spanning more than ten years in private equity. He began his career in manufacturing operations at General Electric/Lockheed Martin and contributed to the successful completion of several commercial and government satellite programs.

    Michael graduated with honors in Mechanical Engineering from Rose-Hulman Institute of Technology, holds an M.S. in Systems Engineering from The Moore School of Engineering of the University of Pennsylvania, and has an M.B.A. in finance and entrepreneurial management from The Wharton School of Business of the University of Pennsylvania. Connect with him on LinkedIn.

    About The Melbourne Entrepreneurial Centre

    The Melbourne Entrepreneurial Centre is situated at the University of Melbourne, the number one ranked university in Australia. Right in the middle of the city of Melbourne, the Centre bridges the critical gap between world-class research and global impact for societal benefit.

    The Melbourne Entrepreneurial Centre cultivates a vibrant entrepreneurial culture by turning ideas and technologies into companies and providing the next generation of entrepreneurial leaders.

    Its collaborative programs connect entrepreneurs with leading industry experts, researchers, investors, and mentors to accelerate venture creation and impact. From ideas to global expansion, the Melbourne Entrepreneurial Centre helps innovators bring transformative ideas to life.

    Mostra di più Mostra meno
    37 min
  • EP117: How One CEO Cleaned Up His Cap Table in Six Months
    Jan 7 2026
    Thomas Jensen didn't leave university research to make more money. He left because he wanted to make a real difference for cancer patients. After 20+ years in oncology and biotech, he's doing exactly that as CEO and co-founder of Allarity Therapeutics. The company he built centers on a radical idea: every patient's cancer is unique, so every treatment should be unique too. Using a proprietary platform that analyzes messenger RNA in tumor cells, Allarity can predict which patients will respond to specific cancer drugs rather than just drug classes. The results speak for themselves. In advanced ovarian cancer patients who often have only 3-4 months to live when they enroll in trials, Allarity's dual-mechanism therapy is showing 25 months overall survival. That's nearly a year better than the best approved drugs on the market, with minimal toxicity. Patients take three capsules a day and go about their lives. Jensen's journey wasn't smooth. When he took over as CEO in December 2023, he inherited a cap table loaded with preferred shares on unfavorable terms. Within six months, he'd cleaned it up completely. By May 2024, every Series A and Series B preferred shareholder had left, and the company was raising capital on favorable terms. Now listed on NASDAQ under ticker ALLR, Allarity is expanding beyond ovarian cancer into small-cell lung cancer through a fully funded VA trial. The goal is to combine their low-toxicity drug with traditional chemotherapy to achieve high response rates without stacking toxic side effects. Jensen's advice for other CEOs facing seemingly impossible challenges? Surround yourself with people who disagree with you. Stay open to different approaches. And remember: it's never too late to right the ship. "Surround yourself with people that you like, but that also disagree with you. Because for me, it has been good to go to people that have a totally different approach on life and things as myself." - Thomas Jensen Key moments in the episode (times are approximate): 02:07 - Overview of Allarity Therapeutics and its mission 02:30 - How the drug response prediction platform works04:31 - Results in advanced ovarian cancer: 25 months overall survival 05:24 - Expansion into small cell lung cancer through VA partnership06:46 - Why Allarity's dual-mechanism drug shows minimal toxicity08:06 - The importance of combining biomarkers with therapies 09:15 - Working with the VA on clinical trials 10:03 - Thomas's early career and decision to leave university research 13:32 - Transition from research to industry and business development 16:18 - Taking over as CEO and inheriting a challenging financial structure 18:52 - The decision-making process for fixing the cap table 22:27 - Importance of advisors and common sense in complex decisions 23:09 - Why CEOs often delay hard decisions that need to be made24:10 - Building relationships with preferred shareholders during the transition25:03 - Timeline: cleaning up the cap table in less than six months 26:07 - What drives Thomas today: deploying precision medicine at scale 28:11 - Advice for CEOs facing significant challenges 29:18 - The value of surrounding yourself with people who disagree with you 30:05 - Final thoughts on persistence and mission-driven leadership About Thomas Jensen: Thomas Jensen is the CEO and co-founder of Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage biopharmaceutical company pioneering personalized cancer treatments. Under his leadership, the company is advancing stenoparib, a dual PARP/WNT inhibitor, through Phase 2 trials in advanced ovarian cancer. Allarity specializes in advancing precision medicines supported by its proprietary Drug Response Predictor (DRP®) companion diagnostic platform. With over 20 years of global biotech and oncology experience, Thomas has held leadership roles across R&D and corporate strategy, and he is passionate about accelerating access to precision therapies for patients with limited treatment options. About Allarity: Allarity Therapeutics is redefining personalized cancer care. The company's lead asset, stenoparib, is a next-generation dual PARP/WNT pathway inhibitor currently in Phase 2 development for advanced ovarian cancer. By leveraging its proprietary Drug Response Predictor (DRP®) companion diagnostic, Allarity aims to match patients with the therapies most likely to benefit them. With a recent Fast Track designation from the FDA and promising data showing a median overall survival of over 25 months, stenoparib is demonstrating potential where many therapies fall short. Allarity is headquartered in Florida, with research operations in Denmark, and remains committed to unlocking the promise of precision oncology. Learn more at www.allarity.com.
    Mostra di più Mostra meno
    25 min
  • EP116:The $100 Million Decision - Choosing Patient Outcomes Over Private Equity
    Dec 18 2025

    When surgeons stop your heart during surgery, who keeps you alive? That's where Chet Czaplicka comes in.

    This Detroit native went from ICU nurse to building the world's largest perfusion company—but not the way you'd think. After seeing post-op cardiac patients in the ICU, Chet asked one simple question: "What exactly do you guys do?" That curiosity launched a 42-year career.

    Perfusionists are the people who become your heart and lungs during surgery. They manage the machines that keep your blood flowing and oxygenated while surgeons work on your stopped heart. During COVID, when patients' lungs failed by the thousands, Chet's teams provided extracorporeal life support at levels he'd never seen in four decades.

    Here's what sets Chet apart: He's turned down multiple private equity offers that would've made him wealthy beyond measure. Why? "I wasn't put on this earth to buy a yacht. My purpose is way different than that."

    Instead, he measures success in reduced kidney injuries, lower stroke rates, and better patient outcomes. He's poured tens of millions back into advancing the technology because, as he puts it, "When I walk out of that operating room, I want to know I delivered the best possible care to that patient."

    From a partnership offer in Fort Wayne he turned down (too small-town for a Detroit guy in his 20s) to building operations across the globe, Chet's story shows what happens when purpose drives profit, not the other way around.

    Chet's Bio:

    Chet Czaplicka is the Founder and CEO of Comprehensive Care Services, a perfusion led company providing perfusion, autotransfusion and related allied health services to hospitals across the United States and internationally. He founded CCS in 2002, building it from a handful of hospital accounts into the largest perfusion provider in the world and now a global perfusion leader. As a practicing perfusionist and registered nurse, Chet keeps CCS focused on patient care, clinical excellence, data-driven decision making and strong hospital partnerships. He continues to lead the organization through growth, innovation and an evolving healthcare landscape.

    Chet on LinkedIn.

    Mostra di più Mostra meno
    44 min
Ancora nessuna recensione